Decreased quality of life of end-stage renal disease is further compromised by renal function replacement treatments such as haemodialysis (HD) and peritoneal dialysis (PD). Poor quality of life negatively affects treatment outcome. This study compared quality of life between HD and PD patients.
Furthermore, the annual cost of renal dialysis is high in developing countries such as South Africa (Dirks & Levin, 2006) . High costs combined with the lack of resources, has meant that rationing of dialysis is common practice (Moosa & Kidd, 2006) . Katz (2005) estimates that there should be roughly 16 000 ESRD patients on renal replacement therapy in South Africa, but that a sizeable number of patients dies without receiving renal replacement therapy.
Given the limited access to renal replacement therapy, due largely to a shortage of facilities and high costs, it is prudent to examine the factors that may decrease the efficiency of treatment. Some of these factors are included in the study of quality of life.
Quality of life of haemodialysis (HD) and peritoneal dialysis (PD) patients.
While the effects of the ESRD on its own are pervasive, the effects of dialysis treatment may prompt further physical and psychological distress for many patients. The burden of illness is therefore not confined to the physical impact of ESRD but encompasses the effects of treatment. The consequences of increasingly poor psychological well-being, superimposed on physical deterioration, may be far-reaching. Renal patients have shown poorer quality of life outcomes than the general population and compare negatively with most other medical patients (Caress, Luker, & Ackrill, 1999) .
Quality of life is broadly defined as a person's sense of well being and ability to function productively in daily life (Williams, 1998) . Mental health problems such as depression are often undetected and therefore untreated in dialysis patients, resulting in further diminished quality of life for the patient (Drayer, et al., 2006) . Some of the physical variables known to influence the quality of life of dialysis patients include years on dialysis treatment (Baiardi, et al., 2002) , age (Baiardi 2002) , dialysis inadequacy and, by implication, the extent of accumulation of uraemic toxins ( Horl, 1998; Kinchen, 2001) , nutritional status and the haemoglobin concentration (Baiardi 2002; Platinga, 2007) .
While it is generally accepted that both HD and PD negatively impact the quality of life, it still remains disputed whether a significant difference exists between the quality of life of patients on HD and those on PD. It is often assumed that patients on PD are better off than those on HD and some of the advantages described for PD above that of HD are the assumption of better prevention of hepatitis C, better management of anaemia, lower costs andperhaps most importantly -more freedom (Pucheu, et al., 2004; Blake, 2001 ).
However, the failure rate with regards to technical aspects is often higher in PD, which then necessitates initiation of HD (Blake, 2001) . The studies of Wu, et al. (2004) and Kontodimopoulos and Niakas, (2008) support the perception that the quality of life for PD patients is better than that of HD patients. In contrast Wasserfallen, et al. (2004) , Killingworth and Van den Akker (1996) and Jager (2004) , found the quality of life to be equally reduced in HD and PD patients. Low quality of life in these patient groups was attributed mainly to experiences of pain/discomfort and anxiety/depression. Instrument. We used the SF-36 (Ware 2008 ) to measure quality of life in patients. The SF-36 is a commonly used measure in quality of life studies (Maor, King, Omer & Mozes, 2001) . It is a 36-item based questionnaire, which assesses the quality of life outcomes of individuals along two main components, namely physical health and mental health.
These components are subdivided into eight categories, which involve questions based on the individual's perception of his/her own health with regards to physical bodily pain and emotional functioning (Ware & Sharebourne, 1992) . The instrument subcategories for mental health refer to the evaluation of vitality, social functioning, emotional roles and emotional aspects, while the physical health subcategories are physical functioning, physical roles, bodily pain and general health.
The SF-36 was designed as a survey for use in clinical practice, research, health policy generation and for the general population. The questionnaire can be self-administered by individuals of 14 years and older (Ware, Keller & Gandek, 1995) . The SF-36 is one of the few generic instruments for the determination of quality of life that has been tested for reliability, validity and responsiveness in the ESRD population (Cagney, 2000) . Reliability of the SF-36 test is high with all dimensions, except that of social functioning, exhibiting Cronbach's alpha scores greater than 0.85 (Brazier, Harper & Jones, 1992) .
The validity and reliability of the test has been established in studies of a Chinese general population (Lam, Tse, Gandek & Fong, 2005 ) and a Swedish general population (Sullivan, Karlsson & Ware, 1995) . The test has been used to examine the health status of various medical subjects, such as chronic fatigue syndrome (Komaroff, et al., 1996) and has on occasion been used to monitor and improve the care of patients in renal units (Kinchen, 2001 ) Table 1 provides a summary of the domains of the SF-36. The meaning of the high and low scores for the domains is also indicated. The means and standard deviations are derived from a survey of the general US population collated by Ware (2008) .
Physiological parameters
Bloods for the determination of the subjects' urea, albumin and haemoglobin levels were collected on days scheduled for treatment. These were sent to the hospital's core laboratory for analysis.
Procedure. Information about the study protocol was presented to the dialysis staff prior to commencement of the study. The patients undertook the SF-36 with the assistance of the dialysis nursing sister where necessary. Data Analysis. The SF-36 scores for the HD and PD patients were compared to each other using Mann-Whitney U test of differences between ranks (BMDP Statistical Software, Inc.). Statistical inference for the analysis was performed using correction for non-parametric distribution of data with pvalues of < 0.05 considered statistically significant. In addition to this analysis, the scores of the scales were compared with respect to age, number of years on treatment and physiological variables.
Results
The mean age and years of treatment for each of the two groups are delineated in Table 2 . Differences in age and years on treatment were statistically non-significant (p=0.469 and p=0.344, respectively).
Differences in Quality of Life in HD and PD Patients Table 3 shows the results of SF-36 for the HD and then PD groups. The HD patients had a mean SF-36 score, which was 109.360 (SD=10.659) or 59.4 % of the total possible score. PD patients had a mean SF-36 score of 105.600 (SD=4.939) or 57.4 % of the total possible score. A t-test indicated nonsignificant differences between the groups in terms of overall SF-36 scores (p=0.244) and this was confirmed by the Mann-Whitney test (p=0.497).
Comparison of Quality of Life with Reference Populations
In terms of norm-base scoring we transformed the scores using a T-score scaling (mean=50, standard deviation=10) (Ware & Sherebourne, 1992) .
These scores can then be compared to various referenced populations, such as the American population, asthma sufferers, and that of others. Figure 1 summarises the norm-based score distribution of the eight aspects measured by the SF-36. The only significant norm-based score difference between the HD and PD patients was found in the bodily pain (BP) category (p<0.05). The degree of bodily pain reported by HD patients was therefore significantly higher than that reported by the PD patients. A comparison was also drawn between the two groups and the scores for the general adult American population (Ware, 2008) . There was no statistically significant difference for either patient group versus the American data when comparing each of the eight aspects.
The statistical analysis results for correlations between the test scores of the SF-36 and patient demographics (age and number of years on treatment) yielded correlation coefficients of r < 0.5 with no statistically significant results. Table 4 indicates the urea, albumin and haemoglobin results for the two patient groups. Mann-Whitney U test statistics indicated no significant difference in urea (p=0.3837) and albumin (p=0.2339) between the HD and PD groups. There was however, a statistically significant difference in haemoglobin (p=0.0107) between the HD and PD groups.
Physiological Measure Comparisons
The mean total SF-36 scores of the two patient groups were correlated to urea, albumin and haemoglobin levels using Spearman correlation coefficients. There were no statistically significant correlations in these data.
These results are reflected in Table 5 .
Discussion
The 36-Item Short-Form Health Survey (SF-36) was used to ascertain the quality of life of HD and PD patients in terms of functional health and wellbeing and to explore whether any differences exist between patients on HD and patients on PD treatment. It is generally known, and could be expected, that quality of life declines in conditions of end stage chronic renal failure.
Although renal replacement therapies such as HD and PD are able to correct some of the homeostatic disturbances and thereby alleviate some of the physical problems, these treatments have potential physical and psychosocial disadvantages, including the time consumed by treatment in hospitals or clinics and the pain associated with treatment. In general, life of end stage chronic renal failure patients on renal function replacement treatments is negatively influenced by the physical symptoms of the disease, as well as by physical and psychosocial aspects of the treatment itself (Kimmel, 2001 ). The majority of these patients suffer severe disturbances of their normal life styles, including disturbances in their careers and their regular roles in family life, a decline in financial stability, a decline in physical and cognitive abilities, depression and, generally, a loss of autonomy (Kimmel, 2002; Kimmel 2001; Kimmel, 1993) .
There is still disagreement about the comparative quality of life between HD and PD patients. A small number of studies has been done on this aspect with each study usually, but not always, confined to a specific centre. Reports from different centres vary with some finding no difference (Jager, 2004) , some reporting a better quality of life in patients on HD (Koorevaar, 2003) and others finding PD patients to have a better quality of life (Wu, 2004) .
In this study quality of life, as reflected by the SF-36 scores, was similar for HD and PD patients. There was thus no significant difference in overall quality of life, as indicated by the SF-36 score. This supports the findings of one of the largest studies abroad (Kutner, 2005) in which quality of life was compared between HD and PD patients.
The two groups investigated in this study were similar with regards to several of the factors known to influence the quality of life: albumin levels -which are often an indication of nutritional status or plasma urea concentration -an indication of dialysis adequacy. The only significant difference between the two groups was the haemoglobin concentrations. Several researchers have previously noted quality of life in dialysis patients to improve with increases in haemoglobin concentrations (Platinga, 2007) . In fact, the degree of anaemia in end stage renal failure is described as an important health outcome measure and has been found to correlate with other clinical symptoms (Kinchen, 2001) . In this study, feasible explanation for the lack of significant overall quality of life difference across the two groups, despite significant differences in haemoglobin concentrations, can probably be found in the fact that both groups were overtly anaemic and that the haemoglobin levels of both groups were significantly lower than normal (Kausz, 2000) . In fact, both the HD and PD groups had haemoglobin levels below the current minimum guideline for haemoglobin concentrations in dialysis patients (11 g/dl) (Platinga, 2007) .
The scores of the two treatment groups were compared for each of the eight aspects measured by the SF-36, namely: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. The only significant difference was found for bodily pain where the PD patients scored significantly lower than HD patients. Bodily pain has previously been found to be one of the factors to impact significantly on the quality of life of dialysis patients (Baiardi 2002 ). There are indeed many factors that can lead to either acute or chronic pain in patients on HD, as well as in patients on PD. It would, however, be speculative to come to any kind of conclusion about the reasons for the differences in body pain found between the two groups in this study. The indication does, nonetheless, warrant a separate study with the focus on body pain due to the fact that no such studies could be found in literature. This is of particular importance in view of the fact that pain (in end-stage chronic renal failure patients on dialysis, as well as in the population in general) is a major confounder of the quality of life, while quality of life is in turn known to be a major determinant of health outcome in end-stage renal failure patients (Kinchen, 2001) .
Conclusion
This study compared the quality of life in end stage chronic renal failure patients on HD and on PD in a renal unit in Tshwane, South Africa. The 
